Balance sheet as at December 31
in CHF | Notes | 2023 | 2022 | |||
Current assets | ||||||
Cash and cash equivalents | 44 757 | 116 430 | ||||
Other current receivables | 5 992 571 | 5 558 139 | ||||
6 037 328 | 5 674 569 | |||||
Non-current assets | ||||||
Investments | 1 177 069 500 | 1 177 069 500 | ||||
1 177 069 500 | 1 177 069 500 | |||||
Total assets | 1 183 106 828 | 1 182 744 069 | ||||
Current liabilities | ||||||
Other current liabilities | 334 219 | 325 013 | ||||
Accrued expenses | 467 774 | 509 994 | ||||
801 993 | 835 007 | |||||
Total liabilities | 801 993 | 835 007 | ||||
Shareholders' equity | ||||||
Share capital | 11 080 000 | 11 080 000 | ||||
Legal capital reserves | ||||||
- Paid-in capital reserve 1) | 20 579 224 | 20 579 224 | ||||
Legal profit reserves | ||||||
- General legal reserve | 4 500 000 | 4 500 000 | ||||
- Reserve for treasury shares 2) | 36 508 182 | 36 508 182 | ||||
Other reserves | 190 319 574 | 190 319 574 | ||||
Retained earnings | 919 317 855 | 918 922 082 | ||||
1 182 304 835 | 1 181 909 062 | |||||
Total liabilities and shareholders' equity | 1 183 106 828 | 1 182 744 069 |
1Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation
2For treasury shares held by subsidiaries
The financial statements were approved by the Board of Directors of BB Biotech AG on February 13, 2024.